Medy-Tox Inc.
Financials
Valuation Metrics
Medy-Tox Inc.'s Market Cap is ₩4751B. At end of 2025 it was ₩8817B. Ranked #459 of 2,414 in KR market (top 19%), #164 of 1,633 on KOSDAQ (top 10%), #48 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 475.13B KRW | KR#459/2,414 Sec#48/231 |
| Revenue | 251.08B KRW | KR#915/2,414 Sec#50/231 |
| Net Income | 15.15B KRW | KR#815/2,414 Sec#54/231 |
| Total Assets | 571.87B KRW | KR#712/2,414 Sec#41/231 |
| Net Assets | 379.35B KRW | KR#615/2,414 Sec#39/231 |
| Employees | 776 | KR#326/2,414 Sec#28/231 |
| Value | ||
| P/E | 31.37x | KR#1,345/2,414 Sec#84/231 |
| P/B | 1.25x | KR#1,687/2,414 Sec#112/231 |
| PEG | 0.14x | KR#507/2,414 Sec#30/231 |
| P/S | 1.89x | KR#1,809/2,414 Sec#104/231 |
| EV/EBITDA | 36.69x | KR#1,278/2,414 Sec#80/231 |
| FCF Yield | 9.63% | KR#645/2,414 Sec#28/231 |
| Profitability | ||
| ROE | 3.99% | KR#1,221/2,414 Sec#85/231 |
| ROA | 2.65% | KR#1,099/2,414 Sec#81/231 |
| Op. Margin | 6.91% | KR#735/2,414 Sec#58/231 |
| Revenue Growth | 7.01% | KR#1,069/2,414 Sec#103/231 |
| Earnings Growth | 216.81% | KR#231/2,414 Sec#14/231 |
| Financial Health | ||
| Debt Ratio | 50.75% | KR#968/2,414 Sec#111/231 |
| Total Debt | 208.24B KRW | KR#504/2,414 Sec#26/231 |
| FCF | 45.75B KRW | KR#323/2,414 Sec#18/231 |
| Cash | 46.93B KRW | KR#771/2,414 Sec#47/231 |
| Current Ratio | 1.03x | KR#1,680/2,414 Sec#169/231 |
| Net Debt/EBITDA | 9.30x | KR#1,197/2,414 Sec#87/231 |
| Dividend | ||
| Div. Yield | 1.88% | KR#943/2,414 Sec#50/231 |
| Div. Growth | 9.09% | KR#619/2,414 Sec#34/231 |
| Performance | ||
| 1Y Return | -45.02% | KR#1,897/2,414 Sec#172/231 |
| 1M Return | -5.38% | KR#1,054/2,414 Sec#101/231 |
| From 52W High | -53.86% | KR#1,405/2,414 Sec#115/231 |
| 1Y MDD | -54.18% | KR#1,166/2,414 Sec#97/231 |
| Trading | ||
| Volume | 18,625 shares | KR#1,868/2,414 Sec#182/231 |
| Trading Value | 1.20B KRW | KR#736/2,414 Sec#78/231 |
| Foreign Own. | 14.32% | KR#335/2,414 Sec#22/231 |
| Per Share | ||
| EPS | 2,076 KRW | KR#439/2,414 Sec#28/231 |
| BPS | 51,976 KRW | KR#258/2,414 Sec#16/231 |
Company Info
Established in 2000 and listed on KOSDAQ in 2009, Meditox engages in the research, development, manufacturing, and sale of Botulinum Toxin Type A and biopharmaceuticals. The company's main products are Meditoxin Inj., Coretox, and Innotox, developed with proprietary original technology. With the KFDA product approval for Neurtoxin in 2023, it is expanding into domestic and international markets while diversifying its portfolio with hyaluronic acid fillers, liquid toxin formulations for US entry, and genetically recombinant toxins. Meditox is headquartered in Cheongwon-gun, Chungcheongbuk-do.